Skip to content

UroGen Pharma URGN Change in AR

Change in AR at other companies

Pfizer logo
PfizerPFE
$65.75M+141%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$595M-35.7%
Merck & Co. logo
Merck & Co.MRK
$272.5M+347%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$700K-95.2%
CG Oncology logo
CG OncologyCGON
$587K
Nuvation Bio logo
Nuvation BioNUVB
$6.65M+154%

Other financials

Income statement

See full
Revenue$51.0M+152%
Gross profit$11.6M
Operating income-$22.8M
Net income-$23.6M+46.2%
EPS (diluted)-$1.17

Balance sheet

See full
Cash & equivalents$110.0M+5.7%
Total debt$197.1M+56.0%
Total equity-$124.3M-167%
Total assets$253.7M+2.5%

Cash flow

See full
Operating cash flow-$45.3M-7.8%
CapEx$54.0K+22.7%
Free cash flow-$45.4M-7.8%

Valuation

See full
Market cap$1.73B+71.7%
Enterprise value$1.81B+80.9%
P/S12.3×+1.3×

Profitability

See full
Gross margin89.7%
Operating margin-329.7%
Net margin-94.8%-25.6pp
FCF margin-118.2%+1.3pp

Returns & leverage

See full
Return on equity-211.6%
Debt / equity4.8×
Current ratio4.7×-1.0×

Where this comes from

Reported directly by UroGen Pharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivable.

The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about UroGen Pharma's change in ar.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is UroGen Pharma's change in AR?
UroGen Pharma (URGN) reported change in AR of $22.33M in Q1 2026.
How has UroGen Pharma's change in AR changed year-over-year?
UroGen Pharma's change in AR increased by 3463.0% year-over-year, from -$664K to $22.33M.
What does change in AR mean?
Increase or decrease in amounts owed by customers — the primary working capital driver for many businesses.